grant
Research Project 1: Nanofibrous Polymer Scaffolds for Immunotherapy to Enhance Efficacy of CAR Therapies for GBM
Organization UNIV OF NORTH CAROLINA CHAPEL HILLLocation CHAPEL HILL, UNITED STATESPosted 5 Mar 2026Deadline 28 Feb 2031
NIHUS FederalResearch GrantFY2026AbscissionAdoptive TransferAgonistAgreementAlginatesAnimal ModelAnimal Models and Related StudiesAntigen TargetingAntigensAssayB7-H3B7H3BioassayBiocompatible MaterialsBiological AssayBiomaterialsBlood leukocyteBody TissuesBolusBolus InfusionBone MarrowBone Marrow Reticuloendothelial SystemBrainBrain CancerBrain Nervous SystemBreast CancerCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD276CD276 geneCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCancer ModelCancer TreatmentCancerModelCancersCell BodyCell Communication and SignalingCell SignalingCell-Mediated Lympholytic CellsCellsChemotherapy and RadiationChemotherapy and/or radiationClinicClinical TrialsCollaborationsCytolytic T-CellCytotoxic T CellCytotoxic T-LymphocytesDeath RateDextransDoseDrug DeliveryDrug Delivery SystemsDrug KineticsDrugsEncephalonEpitope spreadingEvaluationExcisionExtirpationFamilyFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryGenomicsGlioblastomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHomolog of Drosophila TOLLHortega cellHourImmuneImmune MarkersImmune RegulatorsImmune ToleranceImmune infiltratesImmune mediated therapyImmune systemImmunesImmunologic MarkersImmunologic ToleranceImmunologically Directed TherapyImmunomodulatorsImmunostimulatory drugImmunotherapeutic agentImmunotherapyImplantIn VitroInflammatory ResponseInjectionsIntracellular Communication and SignalingIntrasurgical Resection CavityKO miceKineticsKnock-out MiceKnockout MiceLeukocytesLeukocytes Reticuloendothelial SystemLipid ALiteratureLymphocytopeniaLymphoid CellLymphopeniaMacrophageMalignant Breast NeoplasmMalignant Hematopoietic NeoplasmMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant Tumor of the LungMalignant neoplasm of brainMalignant neoplasm of lungMarrow leukocyteMaximal Tolerated DoseMaximally Tolerated DoseMaximum Tolerated DoseMedicationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsMicrogliaModelingMorphologyMurineMusMφNK T cellNK cell immune therapyNK cell immunotherapyNK cell therapyNK cell treatmentNK cell-based immune therapyNK cell-based immunotherapyNK cell-based therapyNK cell-based treatmentNK cellular immunotherapyNK cellular therapyNK immunotherapyNK therapyNK treatmentNKT cellNatural Killer Cell ImmunotherapyNatural Killer T cellNeoplasm MetastasisNull MouseOperative ProceduresOperative Surgical ProceduresOrganPharmaceutical PreparationsPharmacokineticsPolymersPopulationPrimary Brain NeoplasmsPrimary Brain TumorsPrimary NeoplasmPrimary TumorPrognosisPulmonary CancerPulmonary malignant NeoplasmR-Series Research ProjectsR01 MechanismR01 ProgramRNA SeqRNA sequencingRNAseqRadiation therapyRadiotherapeuticsRadiotherapyReceptor CellRecurrenceRecurrentRemovalReportingResearch GrantsResearch Project GrantsResearch ProjectsResearch ProposalsResection CavityResistanceRoleSecondary NeoplasmSecondary TumorSignal TransductionSignal Transduction SystemsSignalingSiteSolid NeoplasmSolid TumorStimulator of Interferon GenesSurgicalSurgical InterventionsSurgical ModelsSurgical ProcedureSurgical RemovalSurgically-Created Cystic Resection CavitySurgically-Created Resection CavitySurvival RateSurvivorsSystemT cells for CART-CellsT-LymphocyteT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTLR proteinTLR4TLR4 geneTLR7TLR7 geneTLR9 geneTLR9 proteinTLR9 receptorTestingTimeTissuesToll HomologueToll-Like Receptor 7Toll-Like Receptor Family GeneToll-like receptorsTreatment EfficacyTumor ImmunityWhite Blood CellsWhite CellWorkanti-cancer therapyanti-tumor immunityantigen spreadingantitumor immunitybiodegradable polymerbiological materialbiological signal transductionbioresorbable polymerblood cancercGAMP STINGcGAMP-STINGcGAMP/STINGcGAS/STINGcancer immunitycancer metastasiscancer of bloodcancer of the bloodcancer therapycancer-directed therapycell killingchemo/radiation therapychemotherapychemotherapy and radiotherapychimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical relevanceclinically relevantcontrolled releasecyclic GMP-AMP synthase/STINGcytokinedegradable polymerdesigndesigningdextrandrug/agentengineered T cellsfightingflow cytophotometrygenetically engineered T-cellsgitter cellglioblastoma multiformeimmune cell infiltrateimmune drugsimmune microenvironmentimmune modulatorsimmune stimulatory agentimmune stimulatory drugimmune stimulatory therapeuticimmune system toleranceimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune unresponsivenessimmune-based biomarkersimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunologic therapeuticsimmunological biomarkersimmunological markersimmunological paralysisimmunomodulatory moleculesimmunoregulatorimmunoregulatory moleculesimmunostimulatory agentsimmunostimulatory biologicsimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimmunotherapeuticsimmunotherapy agentimprovedin vivoinsightinterstitialintervention efficacykiller T celllung cancermalignancymalignant breast tumormesogliamicroglial cellmicrogliocytemigrationmodel of animalmortalitymortality ratemouse modelmurine modelnanofibernanofibrousnatural killer T lymphocytenatural killer cell based immune therapynatural killer cell based immunotherapynatural killer cell therapynatural killer cell treatmentnatural killer cell-based therapynatural killer cellular therapynatural killer therapyneoplasm/cancernew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachorthotopic breast adenocarcinomaorthotopic breast cancerorthotopic breast carcinomaorthotopic breast tumoroverexpressoverexpressionperivascular glial cellpolymerpolymericpre-clinicalpreclinicalradiation or chemotherapyradiation treatmentrecruitresectionresiquimodresistantresponsescaffoldscaffoldingsocial rolespongioblastoma multiformestandard carestandard of carestandard treatmentsubcutaneoussubdermalsuccesssurgerysynergismtherapeutic efficacytherapeutic outcometherapy efficacytherapy outcomethymus derived lymphocytetoll-like receptor 4toll-like receptor 9traffickingtranscriptome sequencingtranscriptomic sequencingtransgenic T- cellstreatment with radiationtumortumor cell metastasistumor immune microenvironmenttumor-immune system interactionswhite blood cellwhite blood corpuscle
Description preview
RP1 ABSTRACT
Glioblastoma (GBM), the most common primary brain tumor, is notoriously resistant to current treatments. Its
prognosis is grim, with a median survival of only 12-15 months after standard treatment, which typically involves
surgical resection followed by radiation and chemotherapy. Despite these efforts, GBM often recurs. New…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click